Nilotinib: A new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia

Pharmacotherapy

Volumn 28, Issue 11 PART 1, 2008, Pages 1374-1382

  Jarkowski III, Anthony ^a   Sweeney, Richard P ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AMN107; Chronic myelogenous leukemia; CML; Dasatinib; Imatinib; Nilotinib

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; APREPITANT; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; CARBAMAZEPINE; CLARITHROMYCIN; CYTARABINE; DASATINIB; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; IMATINIB; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NEFAZODONE; NELFINAVIR; NILOTINIB; PHENOBARBITAL; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RITONAVIR; SAQUINAVIR; TELITHROMYCIN; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CRYSTAL STRUCTURE; CYTOGENETICS; DISEASE COURSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENZYME ACTIVITY; FATIGUE; FOLLOW UP; FOOD DRUG INTERACTION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; LEUKOCYTE; LIVER TOXICITY; MAGNESIUM BLOOD LEVEL; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; POTASSIUM BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 55549093089     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.11.1374     Document Type: Review

References (43)

1. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-56.
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Chronic myelogenous leukemia, 2008. Available from http://www.nccn.org/professionals/physician_gls/PDF/cml.pdf. Accessed February 2, 2008.
3. Ries LAG, Melbert D, Krapcho M, et al, eds. Surveillance epidemiology and end results (SEER) cancer statistics review 1975-2005. Based on November 2007 SEER data submission, posted to the SEER Web site, 2008. Bethesda, MD: National Cancer Institute. Available from http://seer.cancer.gov/ csr/1975_2005/. Accessed February 2, 2008.
4. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-23.
5. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.
6. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 2002;99:1527-35.
7. Guilhot F, Chastang C, Michallet M, et al, for the French Chronic Myeloid Leukemia Study Group. Interferon-alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9.
8. Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992;10:772-8.
9. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
11. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006;20:1767-73.
12. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004;3:1001-10.
13. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:19-26.
14. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology 2005;1:183-7.
15. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
16. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6.
17. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer 2007;110:1178-86.
18. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41. (Erratum in Cancer Cell 2005;7:399.)
19. Rix U, Hantschel O, Durnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055-63.
20. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004;64:672-7.
21. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.
22. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016-19.
23. Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and Philadelphia chromosome-positive leukemogenesis. Cancer Res 2001;61:2343-55.
24. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345-56.
25. Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005;104:1230-6.
26. Kujawski L, Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 2007;48:2310-22.
27. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN 107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108:697-704.
28. Brendel C, Scharenberg C, Dohse M, et al. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007;21:1267-75.
29. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
30. Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) package insert. East Hanover, NJ; 2007.
31. Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. Blood 2007;110(11):1025.
32. Giles FJ, le Coutre P, Bhalla KN, et al. Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) [abstract]. Blood 2007;110(11):1029.
33. Kantarjian HM, Hochhaus A, Cortes J, et al. Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance [abstract]. Blood 2007;110(11):735.
34. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9.
35. U.S. Food and Drug Administration. FDA approval of Tasigna. Available from http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html. Accessed February 2, 2008.
36. U.S. National Institutes of Health. Ongoing clinical trials of nilotinib. Available from http://www.clinicaltrials.gov. Accessed February 2, 2008.
37. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-8.
38. Cortes J, Jabbour E, Hochhaus A, et al. Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant Philadelphia-positive (Ph+) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP) [abstract]. Blood 2007;110(11):1040.
39. Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007;21:2311-15.
40. Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN 107) after blast crisis under imatinib. Bone Marrow Transplant 2007;40:83-4.
41. Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-2.
42. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-16.
43. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metasasis Rev 2003;22:451-64.